Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Pandemrix-induced narcolepsy is associated with genes related to immunity and neuronal survival.

Hallberg P, Smedje H, Eriksson N, Kohnke H, Daniilidou M, Öhman I, Yue QY, Cavalli M, Wadelius C, Magnusson PKE, Landtblom AM, Wadelius M; Swedegene.

EBioMedicine. 2019 Feb;40:595-604. doi: 10.1016/j.ebiom.2019.01.041. Epub 2019 Jan 30.

2.

Drug-Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles.

Nicoletti P, Aithal GP, Chamberlain TC, Coulthard S, Alshabeeb M, Grove JI, Andrade RJ, Bjornsson E, Dillon JF, Hallberg P, Lucena MI, Maitland-van der Zee AH, Martin JH, Molokhia M, Pirmohamed M, Wadelius M, Shen Y, Nelson MR, Daly AK; International Drug-Induced Liver Injury Consortium (iDILIC).

Clin Pharmacol Ther. 2019 Jan 19. doi: 10.1002/cpt.1375. [Epub ahead of print]

PMID:
30661239
3.

Fusidic Acid: A Neglected Risk Factor for Statin-Associated Myopathy.

Rönnqvist J, Hallberg P, Yue QY, Wadelius M.

Clin Med Insights Cardiol. 2018 Dec 4;12:1179546818815162. doi: 10.1177/1179546818815162. eCollection 2018.

4.

Clinical factors predicting drug-induced liver injury due to flucloxacillin.

Lindh M, Hallberg P, Yue QY, Wadelius M.

Drug Healthc Patient Saf. 2018 Nov 21;10:95-101. doi: 10.2147/DHPS.S178394. eCollection 2018.

5.

Common variation near IRF6 is associated with IFN-β-induced liver injury in multiple sclerosis.

Kowalec K, Wright GEB, Drögemöller BI, Aminkeng F, Bhavsar AP, Kingwell E, Yoshida EM, Traboulsee A, Marrie RA, Kremenchutzky M, Campbell TL, Duquette P, Chalasani N, Wadelius M, Hallberg P, Xia Z, De Jager PL, Denny JC, Davis MF, Ross CJD, Tremlett H, Carleton BC.

Nat Genet. 2018 Aug;50(8):1081-1085. doi: 10.1038/s41588-018-0168-y. Epub 2018 Jul 16.

PMID:
30013178
6.

Corrigendum to "Assessment of 105 Patients with Angiotensin Converting Enzyme-Inhibitor Induced Angioedema".

Rasmussen ER, von Buchwald C, Wadelius M, Prasad SC, Kamaleswaran S, Ajgeiy KK, Authried G, Pallesen KAU, Bygum A.

Int J Otolaryngol. 2018 Mar 1;2018:9169414. doi: 10.1155/2018/9169414. eCollection 2018.

7.

Cohort-specific imputation of gene expression improves prediction of warfarin dose for African Americans.

Gottlieb A, Daneshjou R, DeGorter M, Bourgeois S, Svensson PJ, Wadelius M, Deloukas P, Montgomery SB, Altman RB.

Genome Med. 2017 Nov 24;9(1):98. doi: 10.1186/s13073-017-0495-0.

8.

A common missense variant of LILRB5 is associated with statin intolerance and myalgia.

K Siddiqui M, Maroteau C, Veluchamy A, Tornio A, Tavendale R, Carr F, Abelega NU, Carr D, Bloch K, Hallberg P, Yue QY, Pearson ER, Colhoun HM, Morris AD, Dow E, George J, Pirmohamed M, Ridker PM, Doney ASF, Alfirevic A, Wadelius M, Maitland-van der Zee AH, Chasman DI, Palmer CNA; PREDICTION-ADR Consortium.

Eur Heart J. 2017 Dec 21;38(48):3569-3575. doi: 10.1093/eurheartj/ehx467.

9.

CKM Glu83Gly Is Associated With Blunted Creatine Kinase Variation, but Not With Myalgia.

Siddiqui MK, Veluchamy A, Maroteau C, Tavendale R, Carr F, Pearson E, Colhoun H, Morris AD, George J, Doney A, Pirmohamed M, Alfirevic A, Wadelius M, Maitland van der Zee AH, Ridker PM, Chasman DI, Palmer CNA; PREDICTION-ADR Consortium.

Circ Cardiovasc Genet. 2017 Aug;10(4). pii: e001737. doi: 10.1161/CIRCGENETICS.117.001737.

PMID:
28790154
10.

Sulfasalazine-Induced Agranulocytosis Is Associated With the Human Leukocyte Antigen Locus.

Wadelius M, Eriksson N, Kreutz R, Bondon-Guitton E, Ibañez L, Carvajal A, Lucena MI, Sancho Ponce E, Molokhia M, Martin J, Axelsson T, Kohnke H, Yue QY, Magnusson PKE, Bengtsson M, Hallberg P; EuDAC.

Clin Pharmacol Ther. 2018 May;103(5):843-853. doi: 10.1002/cpt.805. Epub 2017 Sep 28.

11.

[Preventive work can reduce drug side effects].

Hallberg P, Collin S, Wadelius M.

Lakartidningen. 2017 Jul 14;114. pii: ERYW. Swedish. No abstract available.

12.

Assessment of 105 Patients with Angiotensin Converting Enzyme-Inhibitor Induced Angioedema.

Rasmussen ER, von Buchwald C, Wadelius M, Prasad SC, Kamaleswaran S, Ajgeiy KK, Authried G, Pallesen KA, Bygum A.

Int J Otolaryngol. 2017;2017:1476402. doi: 10.1155/2017/1476402. Epub 2017 Feb 14. Erratum in: Int J Otolaryngol. 2018 Mar 1;2018:9169414.

13.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.

Johnson JA, Caudle KE, Gong L, Whirl-Carrillo M, Stein CM, Scott SA, Lee MT, Gage BF, Kimmel SE, Perera MA, Anderson JL, Pirmohamed M, Klein TE, Limdi NA, Cavallari LH, Wadelius M.

Clin Pharmacol Ther. 2017 Sep;102(3):397-404. doi: 10.1002/cpt.668. Epub 2017 Apr 4.

14.

Genetic variants associated with angiotensin-converting enzyme inhibitor-induced cough: a genome-wide association study in a Swedish population.

Hallberg P, Persson M, Axelsson T, Cavalli M, Norling P, Johansson HE, Yue QY, Magnusson PK, Wadelius C, Eriksson N, Wadelius M.

Pharmacogenomics. 2017 Feb;18(3):201-213. doi: 10.2217/pgs-2016-0184. Epub 2017 Jan 13.

15.

Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study.

Nicoletti P, Aithal GP, Bjornsson ES, Andrade RJ, Sawle A, Arrese M, Barnhart HX, Bondon-Guitton E, Hayashi PH, Bessone F, Carvajal A, Cascorbi I, Cirulli ET, Chalasani N, Conforti A, Coulthard SA, Daly MJ, Day CP, Dillon JF, Fontana RJ, Grove JI, Hallberg P, Hernández N, Ibáñez L, Kullak-Ublick GA, Laitinen T, Larrey D, Lucena MI, Maitland-van der Zee AH, Martin JH, Molokhia M, Pirmohamed M, Powell EE, Qin S, Serrano J, Stephens C, Stolz A, Wadelius M, Watkins PB, Floratos A, Shen Y, Nelson MR, Urban TJ, Daly AK; International Drug-Induced Liver Injury Consortium, Drug-Induced Liver Injury Network Investigators, and International Serious Adverse Events Consortium.

Gastroenterology. 2017 Apr;152(5):1078-1089. doi: 10.1053/j.gastro.2016.12.016. Epub 2016 Dec 30.

16.

Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study.

Fung P, Bedogni G, Bedogni A, Petrie A, Porter S, Campisi G, Bagan J, Fusco V, Saia G, Acham S, Musto P, Petrucci MT, Diz P, Colella G, Mignogna MD, Pentenero M, Arduino P, Lodi G, Maiorana C, Manfredi M, Hallberg P, Wadelius M, Takaoka K, Leung YY, Bonacina R, Schiødt M, Lakatos P, Taylor T, De Riu G, Favini G, Rogers SN, Pirmohamed M, Nicoletti P; GENVABO Consortium, Fedele S.

Oral Dis. 2017 May;23(4):477-483. doi: 10.1111/odi.12632. Epub 2017 Mar 6.

PMID:
28039941
17.

Comparison of Clinical Factors Between Patients With Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema and Cough.

Hallberg P, Nagy J, Karawajczyk M, Nordang L, Islander G, Norling P, Johansson HE, Kämpe M, Hugosson S, Yue QY, Wadelius M.

Ann Pharmacother. 2017 Apr;51(4):293-300. doi: 10.1177/1060028016682251. Epub 2016 Nov 26.

PMID:
27889699
18.

Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy.

Eriksson N, Wallentin L, Berglund L, Axelsson T, Connolly S, Eikelboom J, Ezekowitz M, Oldgren J, Paré G, Reilly P, Siegbahn A, Syvanen AC, Wadelius C, Yusuf S, Wadelius M.

Pharmacogenomics. 2016 Aug;17(13):1425-39. doi: 10.2217/pgs-2016-0061. Epub 2016 Aug 4.

19.

Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden.

Verhoef TI, Redekop WK, Langenskiold S, Kamali F, Wadelius M, Burnside G, Maitland-van der Zee AH, Hughes DA, Pirmohamed M.

Pharmacogenomics J. 2016 Oct;16(5):478-84. doi: 10.1038/tpj.2016.41. Epub 2016 Jun 7.

PMID:
27272045
20.

Genetic variants associated with antithyroid drug-induced agranulocytosis: a genome-wide association study in a European population.

Hallberg P, Eriksson N, Ibañez L, Bondon-Guitton E, Kreutz R, Carvajal A, Lucena MI, Ponce ES, Molokhia M, Martin J, Axelsson T, Yue QY, Magnusson PK, Wadelius M; EuDAC collaborators.

Lancet Diabetes Endocrinol. 2016 Jun;4(6):507-16. doi: 10.1016/S2213-8587(16)00113-3. Epub 2016 May 3.

PMID:
27157822
21.

Influence of APOE Gene Polymorphism on Interindividual and Interethnic Warfarin Dosage Requirement: A Systematic Review and Meta-Analysis.

Yu WY, Sun X, Wadelius M, Huang L, Peng C, Ma WL, Yang GP.

Cardiovasc Ther. 2016 Oct;34(5):297-307. doi: 10.1111/1755-5922.12186. Review.

PMID:
27062534
22.

Novel regulatory variant detected on the VKORC1 haplotype that is associated with warfarin dose.

Cavalli M, Pan G, Nord H, Eriksson N, Wadelius C, Wadelius M.

Pharmacogenomics. 2016 Aug;17(12):1305-14. doi: 10.2217/pgs-2015-0013. Epub 2016 Feb 5.

23.

Genome-wide association study of warfarin maintenance dose in a Brazilian sample.

Parra EJ, Botton MR, Perini JA, Krithika S, Bourgeois S, Johnson TA, Tsunoda T, Pirmohamed M, Wadelius M, Limdi NA, Cavallari LH, Burmester JK, Rettie AE, Klein TE, Johnson JA, Hutz MH, Suarez-Kurtz G.

Pharmacogenomics. 2015;16(11):1253-63. doi: 10.2217/PGS.15.73. Epub 2015 Aug 12.

24.

Quality of life in patients with venous thromboembolism and atrial fibrillation treated with coumarin anticoagulants.

Marvig CL, Verhoef TI, de Boer A, Kamali F, Redekop K, Pirmohamed M, Daly AK, Manolopoulos VG, Wadelius M, Bouvy M, Maitland-van der Zee AH; EU-PACT consortium.

Thromb Res. 2015 Jul;136(1):69-75. doi: 10.1016/j.thromres.2015.04.026. Epub 2015 Apr 25.

PMID:
25956287
25.

A Bayesian decision support tool for efficient dose individualization of warfarin in adults and children.

Hamberg AK, Hellman J, Dahlberg J, Jonsson EN, Wadelius M.

BMC Med Inform Decis Mak. 2015 Feb 7;15:7. doi: 10.1186/s12911-014-0128-0.

26.

Oral anticoagulation: a critique of recent advances and controversies.

Pirmohamed M, Kamali F, Daly AK, Wadelius M.

Trends Pharmacol Sci. 2015 Mar;36(3):153-63. doi: 10.1016/j.tips.2015.01.003. Epub 2015 Feb 17. Review.

PMID:
25698605
27.

Warfarin pharmacogenetics: it matters if you're black or white.

Wadelius M.

Blood. 2014 Oct 2;124(14):2171. doi: 10.1182/blood-2014-08-594119. No abstract available.

28.

Characteristics associated with drug-induced liver injury from interferon beta in multiple sclerosis patients.

Kowalec K, Kingwell E, Yoshida EM, Marrie RA, Kremenchutzky M, Campbell TL, Wadelius M, Carleton B, Tremlett H.

Expert Opin Drug Saf. 2014 Oct;13(10):1305-17. doi: 10.1517/14740338.2014.947958. Epub 2014 Aug 18.

PMID:
25134421
29.

Phenotype standardization of angioedema in the head and neck region caused by agents acting on the angiotensin system.

Wadelius M, Marshall SE, Islander G, Nordang L, Karawajczyk M, Yue QY, Terreehorst I, Baranova EV, Hugosson S, Sköldefors K, Pirmohamed M, Maitland-van der Zee AH, Alfirevic A, Hallberg P, Palmer CN.

Clin Pharmacol Ther. 2014 Oct;96(4):477-81. doi: 10.1038/clpt.2014.138. Epub 2014 Jun 24.

30.

Patients benefit from genetics-guided coumarin anticoagulant therapy.

Maitland-van der Zee AH, Daly AK, Kamali F, Manolopoulous VG, Verhoef TI, Wadelius M, de Boer A, Pirmohamed M; EU-PACT Study Group.

Clin Pharmacol Ther. 2014 Jul;96(1):15-7. doi: 10.1038/clpt.2014.44. Erratum in: Clin Pharmacol Ther. 2014 Sep;96(3):397. Manolopoulos, V G [corrected to Manolopoulous, V G].

PMID:
24942396
31.

The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.

Ramsey LB, Johnson SG, Caudle KE, Haidar CE, Voora D, Wilke RA, Maxwell WD, McLeod HL, Krauss RM, Roden DM, Feng Q, Cooper-DeHoff RM, Gong L, Klein TE, Wadelius M, Niemi M.

Clin Pharmacol Ther. 2014 Oct;96(4):423-8. doi: 10.1038/clpt.2014.125. Epub 2014 Jun 11.

32.

Phenotype standardization for statin-induced myotoxicity.

Alfirevic A, Neely D, Armitage J, Chinoy H, Cooper RG, Laaksonen R, Carr DF, Bloch KM, Fahy J, Hanson A, Yue QY, Wadelius M, Maitland-van Der Zee AH, Voora D, Psaty BM, Palmer CN, Pirmohamed M.

Clin Pharmacol Ther. 2014 Oct;96(4):470-6. doi: 10.1038/clpt.2014.121. Epub 2014 Jun 4.

33.

Genotype-guided dosing of vitamin K antagonists.

Pirmohamed M, Wadelius M, Kamali F; EU-PACT Group.

N Engl J Med. 2014 May 1;370(18):1764-5. doi: 10.1056/NEJMc1402521. No abstract available.

PMID:
24804303
34.

The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis.

Dias MM, Pignon JP, Karapetis CS, Boige V, Glimelius B, Kweekel DM, Lara PN, Laurent-Puig P, Martinez-Balibrea E, Páez D, Punt CJ, Redman MW, Toffoli G, Wadelius M, McKinnon RA, Sorich MJ.

Pharmacogenomics J. 2014 Oct;14(5):424-31. doi: 10.1038/tpj.2014.16. Epub 2014 Apr 8.

PMID:
24709690
35.

Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.

Rosmarin D, Palles C, Church D, Domingo E, Jones A, Johnstone E, Wang H, Love S, Julier P, Scudder C, Nicholson G, Gonzalez-Neira A, Martin M, Sargent D, Green E, McLeod H, Zanger UM, Schwab M, Braun M, Seymour M, Thompson L, Lacas B, Boige V, Ribelles N, Afzal S, Enghusen H, Jensen SA, Etienne-Grimaldi MC, Milano G, Wadelius M, Glimelius B, Garmo H, Gusella M, Lecomte T, Laurent-Puig P, Martinez-Balibrea E, Sharma R, Garcia-Foncillas J, Kleibl Z, Morel A, Pignon JP, Midgley R, Kerr D, Tomlinson I.

J Clin Oncol. 2014 Apr 1;32(10):1031-9. doi: 10.1200/JCO.2013.51.1857. Epub 2014 Mar 3. Review.

36.

Pharmacogenetics-based warfarin dosing in children.

Hamberg AK, Wadelius M.

Pharmacogenomics. 2014 Feb;15(3):361-74. doi: 10.2217/pgs.14.8. Review.

37.

Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process.

Caudle KE, Klein TE, Hoffman JM, Muller DJ, Whirl-Carrillo M, Gong L, McDonagh EM, Sangkuhl K, Thorn CF, Schwab M, Agundez JA, Freimuth RR, Huser V, Lee MT, Iwuchukwu OF, Crews KR, Scott SA, Wadelius M, Swen JJ, Tyndale RF, Stein CM, Roden D, Relling MV, Williams MS, Johnson SG.

Curr Drug Metab. 2014 Feb;15(2):209-17.

38.

Characterizing variability in warfarin dose requirements in children using modelling and simulation.

Hamberg AK, Wadelius M, Friberg LE, Biss TT, Kamali F, Jonsson EN.

Br J Clin Pharmacol. 2014 Jul;78(1):158-69. doi: 10.1111/bcp.12308.

39.

A randomized trial of genotype-guided dosing of warfarin.

Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, Kesteven P, Christersson C, Wahlström B, Stafberg C, Zhang JE, Leathart JB, Kohnke H, Maitland-van der Zee AH, Williamson PR, Daly AK, Avery P, Kamali F, Wadelius M; EU-PACT Group.

N Engl J Med. 2013 Dec 12;369(24):2294-303. doi: 10.1056/NEJMoa1311386. Epub 2013 Nov 19.

40.

A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon.

Verhoef TI, Ragia G, de Boer A, Barallon R, Kolovou G, Kolovou V, Konstantinides S, Le Cessie S, Maltezos E, van der Meer FJ, Redekop WK, Remkes M, Rosendaal FR, van Schie RM, Tavridou A, Tziakas D, Wadelius M, Manolopoulos VG, Maitland-van der Zee AH; EU-PACT Group.

N Engl J Med. 2013 Dec 12;369(24):2304-12. doi: 10.1056/NEJMoa1311388. Epub 2013 Nov 19.

41.

Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.

Perera MA, Cavallari LH, Limdi NA, Gamazon ER, Konkashbaev A, Daneshjou R, Pluzhnikov A, Crawford DC, Wang J, Liu N, Tatonetti N, Bourgeois S, Takahashi H, Bradford Y, Burkley BM, Desnick RJ, Halperin JL, Khalifa SI, Langaee TY, Lubitz SA, Nutescu EA, Oetjens M, Shahin MH, Patel SR, Sagreiya H, Tector M, Weck KE, Rieder MJ, Scott SA, Wu AH, Burmester JK, Wadelius M, Deloukas P, Wagner MJ, Mushiroda T, Kubo M, Roden DM, Cox NJ, Altman RB, Klein TE, Nakamura Y, Johnson JA.

Lancet. 2013 Aug 31;382(9894):790-6. doi: 10.1016/S0140-6736(13)60681-9. Epub 2013 Jun 5.

42.

[Pharmacogenetic analysis can predict adverse effects of statins].

Garwicz D, Wadelius M.

Lakartidningen. 2013 May 7-21;110(19-20):951-2. Swedish. No abstract available.

PMID:
23745502
43.

Genetic determinants of dabigatran plasma levels and their relation to bleeding.

Paré G, Eriksson N, Lehr T, Connolly S, Eikelboom J, Ezekowitz MD, Axelsson T, Haertter S, Oldgren J, Reilly P, Siegbahn A, Syvanen AC, Wadelius C, Wadelius M, Zimdahl-Gelling H, Yusuf S, Wallentin L.

Circulation. 2013 Apr 2;127(13):1404-12. doi: 10.1161/CIRCULATIONAHA.112.001233. Epub 2013 Mar 6.

PMID:
23467860
44.

Warfarin dose prediction in children using pharmacometric bridging--comparison with published pharmacogenetic dosing algorithms.

Hamberg AK, Friberg LE, Hanséus K, Ekman-Joelsson BM, Sunnegårdh J, Jonzon A, Lundell B, Jonsson EN, Wadelius M.

Eur J Clin Pharmacol. 2013 Jun;69(6):1275-83. doi: 10.1007/s00228-012-1466-4. Epub 2013 Jan 11. Erratum in: Eur J Clin Pharmacol. 2013 Sep;69(9):1737.

45.

miR-133a regulates vitamin K 2,3-epoxide reductase complex subunit 1 (VKORC1), a key protein in the vitamin K cycle.

Pérez-Andreu V, Teruel R, Corral J, Roldán V, García-Barberá N, Salloum-Asfar S, Gómez-Lechón MJ, Bourgeois S, Deloukas P, Wadelius M, Vicente V, González-Conejero R, Martínez C.

Mol Med. 2013 Jan 22;18:1466-72. doi: 10.2119/molmed.2012.00062.

46.

Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs.

Verhoef TI, Redekop WK, van Schie RM, Bayat S, Daly AK, Geitona M, Haschke-Becher E, Hughes DA, Kamali F, Levin LÅ, Manolopoulos VG, Pirmohamed M, Siebert U, Stingl JC, Wadelius M, de Boer A, Maitland-van der Zee AH; EU-PACT group.

Pharmacogenomics. 2012 Sep;13(12):1405-17. Review.

PMID:
22966889
47.

Warfarin dose prediction in children using pharmacogenetics information.

Biss T, Hamberg AK, Avery P, Wadelius M, Kamali F.

Br J Haematol. 2012 Oct;159(1):106-9. doi: 10.1111/j.1365-2141.2012.09230.x. Epub 2012 Jul 18. No abstract available.

PMID:
22804567
48.

The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.

Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, Krauss RM, Roden DM, Feng Q, Cooper-Dehoff RM, Gong L, Klein TE, Wadelius M, Niemi M; Clinical Pharmacogenomics Implementation Consortium (CPIC).

Clin Pharmacol Ther. 2012 Jul;92(1):112-7. doi: 10.1038/clpt.2012.57. Epub 2012 May 23.

49.

Prediction of warfarin dose: why, when and how?

Eriksson N, Wadelius M.

Pharmacogenomics. 2012 Mar;13(4):429-40. doi: 10.2217/pgs.11.184. Review.

50.

Pharmacogenomics and personalized medicine: the plunge into next-generation sequencing.

Wadelius M, Alfirevic A.

Genome Med. 2011 Dec 28;3(12):78. doi: 10.1186/gm294.

Supplemental Content

Loading ...
Support Center